Sheryl Stevenson

Incoming ARVO president SriniVas R. Sadda, MD, discussed major challenges in vision science research and how annual meetings inspire innovation in ophthalmology

David Lubeck, MD, talks about the biggest surprises from ASCRS in the glaucoma space

Josefina Botta, MD, MSc, discusses her real-world experiences with the RayOne EMV toric lens

The technology, which creates a 360-degree, instantaneous capsulotomy, appeared at the Eyecelerator event

Dr Nir Shoham-Hazon presented two papers detailing outcomes from the iTrack microcatheter at ASCRS in Boston

Elizabeth Yeu, MD, discusses a corneal case report at ASCRS 2024

At ASCRS, Dr Rom Kandavel discusses iStent outcomes for patients who have undergone laser peripheral iridotomy, trabeculectomy and SLT

William F. Wiley, MD, shares key takeaways from his presentation on binocularity and stereoacuity

Dr Neda Nikpoor discusses Light Adjustable Lenses and the implications for clinicians at ASCRS 2024

At ASCRS 2024, Aurion Biotech's Global VP Eris Jordan previews upcoming clinical data from North America and Asia

At the 2024 ASCRS meeting, Anthony Wallace details the presentations and educational programmes from Bausch + Lomb

At the ASCRS meeting in Boston, Dan Tran, MD, details his presentation on incision quality and clinical outcomes of femtosecond laser

At ASCRS in Boston, Paul Harasymowycz, MD shared a decade's worth of data on MIGS procedures for primary open-angle glaucoma

Adam Muzychuk, MD, BSc, FRCSC, discusses his ASCRS 2024 presentation on toric lens use for patients with low astigmatism

Greg Kunst, CEO of Aurion Biotech, discusses AURN001, a novel cell therapy targeting corneal endothelial disease

At ASCRS2024, George O. Waring IV, MD, FACS, provides an overview of his presentation highlighting outcomes for LASIK performed using an updated laser ablation algorithm

Sean Hanlon, CEO of CoFi, details the patient and provider benefits of recent CareCredit integration

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

Andrew G. Lee, MD, expresses his perspective regarding the necessity of lumbar puncture for all individuals with idiopathic intracranial hypertension, highlighting the importance of clinical judgment and treatment approaches.

Dr Baruch Kuppermann discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular oedema and retinal vein occlusion.

Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualisation and patients who have undergone small aperture IOL implantation at this year's American Academy of Ophthalmology meeting

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Penny Asbell, MD, FACS, presented results from the ARMOR Study

At this year's American Academy of Ophthalmology meeting, the Ophthalmology Times team spoke with Megan Baldwin, MD, founder of Opthea Limited, about the company's ShORe and COAST clinical trials

At AAO 2023, Rich Small, CEO of Neurotech, spoke with our team about the company's development of encapsulated cell therapy, NT-501

At the 2023 AAO meeting, Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

At this year's American Academy of Ophthalmology meeting, Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America, spoke with us about three exciting new launches

Ben Bergo, CEO of Visus Therapeutics, spoke with Ophthalmology Times about the BRIO-I study on presbyopia

Peter K. Kaiser, MD, provides an overview of innovative therapies in development for patients with dry age-related macular degeneration.